Information Provided By:
Fly News Breaks for March 5, 2019
CTIC
Mar 5, 2019 | 09:03 EDT
Lake Street analyst Thomas Flaten started CTI BioPharma with a Buy rating and $4 price target. The company's targeted indication for pacritinib in myelofibrosis with severe thrombocytopenia represents an unmet clinical need and potential revenue opportunity of $450M, Flaten tells investors in a research note. Further, CTI's other compounds are not being developed for this niche indication, providing a "substantial pay-off" for the company should the clinical development of pacritinib bear fruit, says the analyst.
News For CTIC From the Last 2 Days
There are no results for your query CTIC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.